Content :
Cardiovascular diseases
Products organised per phase
| Phase |
Product |
Product |
Product |
Product |
| Approved / Launched / LCM |
APROVEL®
irbesartan
Type 2 diabetic nephropathy;
reduced mass tablet
formulation, US/EU; CHF;
Severe hypertension, EU/US; combo HCTZ
300-25 mg, US/EU
|
- |
- |
- |
| Submitted |
- |
- |
- |
- |
| Phase III |
XRP0038
NV1FGF
Critical Limb Ischemia (CLI)
|
MULTAQ®
dronedarone
Antiarrhythmic agent
Atrial fibrillation
|
APROVEL®
irbesartan
CHF with preserved systolic
functions; Atrial fibrillation
|
- |
| Phase IIb |
ataciguat
(HMR1766)
Guanylate cyclase
activator
Peripheral Arterial Disease (PAD)
|
ilepatril
(AVE7688)
ACE/NEP inhibitor
Uncontrolled hypertension;
Chronic kidney disease
|
celivarone
(SSR149744)
Antiarrhythmic agent
Atrial fibrillation
|
SL65.0472
5-HT1B/5-HT2A
antagonist
Peripheral Arterial
Disease (PAD)
|
| Phase IIa |
- |
- |
- |
- |
| Phase I |
AVE0657
NHE3 Inhibitor
Sleep apnea
|
AVE3085
e-NOS transcription
enhancer
CHF
|
- |
- |
| Preclinical |
AVE0118
K+ channel blocker
Obstructive sleep apnea
(nasal route)
|
SAR106881
FGF agonist
Post-ischemic revascularization
|
SAR114646
Antiarrhythmic agent
IV treatment of atrial and
ventricular arrhythmias
|
SAR407899
Rho-kinase inhibitor
Hypertension; Neuropathic pain
|
R&D portfolio presented on February 12, 2008
|
